FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2561172014> ?p ?o ?g. }

• W2561172014 abstract "Several groups have emphasized on the functional role of phytochemicals in chemoprevention and chemotherapy of prostate cancer (CaP). In this study we have focused on Withaferin A (WA) a bioactive compound derived from Withania somnifera, which has been extensively used in Asian and African traditional medicine system. In our in vitro studies, WA inhibits the growth of CRPC cells by targeting AKT mediated pro-survival signaling and simultaneously activating FOXO3a dependent apoptosis in CaP cell lines. The objective of the present study was to evaluate the in vivo efficacy of WA on both xenograft and transgenic adenocarcinoma of mouse prostrate (TRAMP) models. DU-145 and C4-2B CaP cells stably overexpressing AKT were xenografted in nude mice and WA (5mg/kg body weight) was orally administered along with control groups fed with oil alone for 4-5 weeks. AKT-overexpressing tumors showed 2-3-fold faster growth than pCMV-expressing tumors and oral administration of WA significantly reduced AKT-induced tumor growth. Immunohistochemistry of tumor sections revealed high expression of AKT, pAKT and down regulation of nuclear FOXO3a in tumor sections derived from AKT-overexpressing tumors. On the contrary, WA treated controls as well as AKT over expressed tumor sections clearly revealed that WA reverted FOXO3a mediated apoptotic signaling by down regulating AKT activation. In addition, activation of AKT has emerged as a central feature of epithelial-mesenchymal transition (EMT). Our results also revealed elevated expression of important EMT related transcription factors and genes such as snail, slug, β-catenin, vimentin, and MMPs and decrease in the expression of E-cadherin expression in AKT overexpressing tumors. Simultaneously, WA treatment of pCMV and AKT-overexpressing tumors showed decrease in the expression of these EMT markers and increase in the expression of E-cadherin. Similarly, TRAMP mice were randomized into controls and WA (oral gavage-3mg/kg body weight) for 31 weeks. Control and WA-treated mice were sacrificed periodically at 11, 20, 27 and 31 weeks. Histopathological examination revealed both the groups (control and WA-treated) showed prostatic hyperplasia with no signs of metastasis up to 20 weeks. However, 58.3% mice in the control group showed metastasis to lungs, liver or kidneys, whereas in the treatment group 16.6% mice showed metastasis in 31 weeks. Molecular analysis showed higher expression of phosphorylated AKT, FOXO3a, along with EMT markers like β-catenin, snail, vimentin and down regulation of E-cadherin expression in control-TRAMP tumors. On the other hand, WA-treated tumor tissues revealed low expression of pAKT and pFOXO3a in WA treated mice. Also, low expression of β-catenin; snail, vimentin and upregulation of E-cadherin in WA treated mice was observed. These results potentiate the chemopreventive and chemotherapeutic effects of WA in CaP and steers the clinical translation of this biomolecule. Citation Format: Suman Suman, Trinath P. Das, Murali K. Ankem, Chendil Damodaran. Chemopreventive and chemotherapeutic effect of Withaferin-A on in vivo models of prostate cancer. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4114. doi:10.1158/1538-7445.AM2015-4114" @default.
• W2561172014 created "2017-01-06" @default.
• W2561172014 creator A5044485769 @default.
• W2561172014 creator A5052834942 @default.
• W2561172014 creator A5058310383 @default.
• W2561172014 creator A5077759533 @default.
• W2561172014 date "2015-08-01" @default.
• W2561172014 modified "2023-09-25" @default.
• W2561172014 title "Abstract 4114: Chemopreventive and chemotherapeutic effect of Withaferin-A on in vivo models of prostate cancer" @default.
• W2561172014 doi "https://doi.org/10.1158/1538-7445.am2015-4114" @default.
• W2561172014 hasPublicationYear "2015" @default.
• W2561172014 type Work @default.
• W2561172014 sameAs 2561172014 @default.
• W2561172014 citedByCount "0" @default.
• W2561172014 crossrefType "proceedings-article" @default.
• W2561172014 hasAuthorship W2561172014A5044485769 @default.
• W2561172014 hasAuthorship W2561172014A5052834942 @default.
• W2561172014 hasAuthorship W2561172014A5058310383 @default.
• W2561172014 hasAuthorship W2561172014A5077759533 @default.
• W2561172014 hasConcept C121608353 @default.
• W2561172014 hasConcept C126322002 @default.
• W2561172014 hasConcept C142724271 @default.
• W2561172014 hasConcept C147447768 @default.
• W2561172014 hasConcept C150903083 @default.
• W2561172014 hasConcept C190283241 @default.
• W2561172014 hasConcept C204232928 @default.
• W2561172014 hasConcept C204787440 @default.
• W2561172014 hasConcept C207001950 @default.
• W2561172014 hasConcept C2776235491 @default.
• W2561172014 hasConcept C2776598214 @default.
• W2561172014 hasConcept C2780069950 @default.
• W2561172014 hasConcept C2780192828 @default.
• W2561172014 hasConcept C2780940892 @default.
• W2561172014 hasConcept C502942594 @default.
• W2561172014 hasConcept C55493867 @default.
• W2561172014 hasConcept C71924100 @default.
• W2561172014 hasConcept C75217442 @default.
• W2561172014 hasConcept C86554907 @default.
• W2561172014 hasConcept C86803240 @default.
• W2561172014 hasConceptScore W2561172014C121608353 @default.
• W2561172014 hasConceptScore W2561172014C126322002 @default.
• W2561172014 hasConceptScore W2561172014C142724271 @default.
• W2561172014 hasConceptScore W2561172014C147447768 @default.
• W2561172014 hasConceptScore W2561172014C150903083 @default.
• W2561172014 hasConceptScore W2561172014C190283241 @default.
• W2561172014 hasConceptScore W2561172014C204232928 @default.
• W2561172014 hasConceptScore W2561172014C204787440 @default.
• W2561172014 hasConceptScore W2561172014C207001950 @default.
• W2561172014 hasConceptScore W2561172014C2776235491 @default.
• W2561172014 hasConceptScore W2561172014C2776598214 @default.
• W2561172014 hasConceptScore W2561172014C2780069950 @default.
• W2561172014 hasConceptScore W2561172014C2780192828 @default.
• W2561172014 hasConceptScore W2561172014C2780940892 @default.
• W2561172014 hasConceptScore W2561172014C502942594 @default.
• W2561172014 hasConceptScore W2561172014C55493867 @default.
• W2561172014 hasConceptScore W2561172014C71924100 @default.
• W2561172014 hasConceptScore W2561172014C75217442 @default.
• W2561172014 hasConceptScore W2561172014C86554907 @default.
• W2561172014 hasConceptScore W2561172014C86803240 @default.
• W2561172014 hasLocation W25611720141 @default.
• W2561172014 hasOpenAccess W2561172014 @default.
• W2561172014 hasPrimaryLocation W25611720141 @default.
• W2561172014 hasRelatedWork W1969271264 @default.
• W2561172014 hasRelatedWork W2000250011 @default.
• W2561172014 hasRelatedWork W2014128084 @default.
• W2561172014 hasRelatedWork W2026120060 @default.
• W2561172014 hasRelatedWork W2034146803 @default.
• W2561172014 hasRelatedWork W2036281813 @default.
• W2561172014 hasRelatedWork W2042245924 @default.
• W2561172014 hasRelatedWork W2057505610 @default.
• W2561172014 hasRelatedWork W2089506765 @default.
• W2561172014 hasRelatedWork W2139720322 @default.
• W2561172014 hasRelatedWork W2155081607 @default.
• W2561172014 hasRelatedWork W2184397248 @default.
• W2561172014 hasRelatedWork W2334910644 @default.
• W2561172014 hasRelatedWork W2499870864 @default.
• W2561172014 hasRelatedWork W2593375664 @default.
• W2561172014 hasRelatedWork W2809905267 @default.
• W2561172014 hasRelatedWork W2954134624 @default.
• W2561172014 hasRelatedWork W3031241470 @default.
• W2561172014 hasRelatedWork W3214374351 @default.
• W2561172014 hasRelatedWork W2605684978 @default.
• W2561172014 isParatext "false" @default.
• W2561172014 isRetracted "false" @default.
• W2561172014 magId "2561172014" @default.
• W2561172014 workType "article" @default.